Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
WYTENSIN (guanabenz acetate) is an oral antihypertensive agent approved in 1982 that works as a centrally acting alpha-2 adrenergic agonist to reduce blood pressure. It is used to treat hypertension in patients requiring oral medication management. The drug operates by stimulating alpha-2 receptors in the central nervous system to decrease sympathetic outflow and lower peripheral vascular resistance.
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating a mature brand with limited growth trajectory and likely smaller team investments.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on WYTENSIN offers limited career growth given the LOE-approaching lifecycle and zero linked job openings; roles are primarily defensive, focused on maintaining existing market share and managing competitive erosion. This product is better suited for early-career professionals seeking foundational commercial experience or those willing to manage a mature product with stable but declining revenue.
Worked on WYTENSIN at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.